AU2005282397A1 - Methods of using death receptor ligands and CD20 antibodies - Google Patents
Methods of using death receptor ligands and CD20 antibodies Download PDFInfo
- Publication number
- AU2005282397A1 AU2005282397A1 AU2005282397A AU2005282397A AU2005282397A1 AU 2005282397 A1 AU2005282397 A1 AU 2005282397A1 AU 2005282397 A AU2005282397 A AU 2005282397A AU 2005282397 A AU2005282397 A AU 2005282397A AU 2005282397 A1 AU2005282397 A1 AU 2005282397A1
- Authority
- AU
- Australia
- Prior art keywords
- antibody
- antibodies
- receptor
- apo
- ligand
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60783404P | 2004-09-08 | 2004-09-08 | |
US60/607,834 | 2004-09-08 | ||
US66655005P | 2005-03-30 | 2005-03-30 | |
US60/666,550 | 2005-03-30 | ||
PCT/US2005/032015 WO2006029275A2 (en) | 2004-09-08 | 2005-09-07 | Methods of using death receptor ligands and cd20 antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2005282397A1 true AU2005282397A1 (en) | 2006-03-16 |
Family
ID=35788041
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2005282397A Abandoned AU2005282397A1 (en) | 2004-09-08 | 2005-09-07 | Methods of using death receptor ligands and CD20 antibodies |
Country Status (13)
Country | Link |
---|---|
US (2) | US20090175854A1 (zh) |
EP (1) | EP1802660A2 (zh) |
JP (1) | JP2008512479A (zh) |
KR (1) | KR20070050951A (zh) |
CN (1) | CN101048428A (zh) |
AU (1) | AU2005282397A1 (zh) |
BR (1) | BRPI0515604A (zh) |
CA (1) | CA2577828A1 (zh) |
IL (1) | IL181315A0 (zh) |
NO (1) | NO20071789L (zh) |
NZ (1) | NZ553171A (zh) |
RU (1) | RU2007112952A (zh) |
WO (1) | WO2006029275A2 (zh) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005044859A2 (en) | 2003-11-05 | 2005-05-19 | Glycart Biotechnology Ag | Cd20 antibodies with increased fc receptor binding affinity and effector function |
AU2005227322A1 (en) | 2004-03-23 | 2005-10-06 | Biogen Idec Ma Inc. | Receptor coupling agents and therapeutic uses thereof |
WO2008066854A2 (en) * | 2006-11-28 | 2008-06-05 | Novartis Ag | Methods and compositions for inducing apoptosis in cancer cells |
WO2009040811A2 (en) | 2007-09-24 | 2009-04-02 | Bar-Ilan University | Polymer nanoparticles coated by magnetic metal oxide and uses thereof |
AR073295A1 (es) | 2008-09-16 | 2010-10-28 | Genentech Inc | Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion. |
AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
KR101853702B1 (ko) | 2009-12-07 | 2018-05-03 | 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 | 항-종양 항체 치료를 향상시키는 방법 |
SI2516469T1 (sl) | 2009-12-22 | 2016-05-31 | Roche Glycart Ag | Protitelesa proti her3 in uporabe le-teh |
AR094403A1 (es) | 2013-01-11 | 2015-07-29 | Hoffmann La Roche | Terapia de combinación de anticuerpos anti-her3 |
AU2015380455A1 (en) | 2015-01-26 | 2017-08-03 | Macrogenics, Inc. | Multivalent molecules comprising DR5-binding domains |
US20180206726A1 (en) | 2016-12-07 | 2018-07-26 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
US20210138213A1 (en) | 2017-03-30 | 2021-05-13 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
US20230041197A1 (en) | 2018-06-20 | 2023-02-09 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
WO2019246317A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease or condition in a tissue originating from the endoderm |
WO2020106704A2 (en) | 2018-11-19 | 2020-05-28 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
WO2021119482A1 (en) | 2019-12-13 | 2021-06-17 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5871996A (en) * | 1994-02-04 | 1999-02-16 | Bio Merieux | Retrovirus agents MSRV1 and MSRV2 associated with multiple sclerosis |
IL85035A0 (en) * | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
US5736137A (en) * | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
JP4435304B2 (ja) * | 1995-06-29 | 2010-03-17 | イミュネックス・コーポレーション | アポトーシスを誘導するサイトカイン |
US6030945A (en) * | 1996-01-09 | 2000-02-29 | Genentech, Inc. | Apo-2 ligand |
US6998116B1 (en) * | 1996-01-09 | 2006-02-14 | Genentech, Inc. | Apo-2 ligand |
PT1012274E (pt) * | 1997-01-28 | 2007-08-14 | Craig A Rosen | Receptor 4 contendo um domínio de morte (dm4; receptor de morte 4), membro da super-família do ftn e ligação a liart (ap02) |
US6433147B1 (en) * | 1997-01-28 | 2002-08-13 | Human Genome Sciences, Inc. | Death domain containing receptor-4 |
US6072047A (en) * | 1997-02-13 | 2000-06-06 | Immunex Corporation | Receptor that binds trail |
US20020160446A1 (en) * | 2000-11-14 | 2002-10-31 | Holtzman Douglas A. | Novel genes encoding proteins having prognostic diagnostic preventive therapeutic and other uses |
US20010010924A1 (en) * | 1997-03-14 | 2001-08-02 | Keith Charles Deen | Tumor necrosis factor related receptor, tr6 polynecleotides |
US6313269B1 (en) * | 1997-03-14 | 2001-11-06 | Smithkline Beecham Corporation | Tumor necrosis factor related receptor, TR6 |
US6872568B1 (en) * | 1997-03-17 | 2005-03-29 | Human Genome Sciences, Inc. | Death domain containing receptor 5 antibodies |
CN1184315C (zh) * | 1997-03-17 | 2005-01-12 | 人类基因组科学公司 | 包含死亡结构域的受体-5 |
AU7126498A (en) * | 1997-04-16 | 1998-11-11 | Millennium Pharmaceuticals, Inc. | Tumor necrosis factor receptor related proteins tango-63d and tango-63e |
US6342369B1 (en) * | 1997-05-15 | 2002-01-29 | Genentech, Inc. | Apo-2-receptor |
IL137176A0 (en) * | 1998-01-26 | 2001-07-24 | Genentech Inc | Antibodies to 4dr and uses thereof |
US6252050B1 (en) * | 1998-06-12 | 2001-06-26 | Genentech, Inc. | Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method |
EP1401476A4 (en) * | 2001-03-14 | 2006-03-08 | Genentech Inc | IGF ANTAGONIST PEPTIDES |
CA2465314C (en) * | 2001-11-01 | 2013-12-10 | The Uab Research Foundation | Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents |
-
2005
- 2005-09-07 CN CNA2005800364755A patent/CN101048428A/zh active Pending
- 2005-09-07 CA CA002577828A patent/CA2577828A1/en not_active Abandoned
- 2005-09-07 RU RU2007112952/13A patent/RU2007112952A/ru not_active Application Discontinuation
- 2005-09-07 KR KR1020077005375A patent/KR20070050951A/ko not_active Application Discontinuation
- 2005-09-07 JP JP2007531333A patent/JP2008512479A/ja active Pending
- 2005-09-07 NZ NZ553171A patent/NZ553171A/en not_active IP Right Cessation
- 2005-09-07 AU AU2005282397A patent/AU2005282397A1/en not_active Abandoned
- 2005-09-07 BR BRPI0515604-1A patent/BRPI0515604A/pt not_active IP Right Cessation
- 2005-09-07 WO PCT/US2005/032015 patent/WO2006029275A2/en active Application Filing
- 2005-09-07 EP EP05795474A patent/EP1802660A2/en not_active Withdrawn
- 2005-09-07 US US11/662,315 patent/US20090175854A1/en not_active Abandoned
-
2006
- 2006-10-03 US US11/542,330 patent/US20070231324A1/en not_active Abandoned
-
2007
- 2007-02-13 IL IL181315A patent/IL181315A0/en unknown
- 2007-04-04 NO NO20071789A patent/NO20071789L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2577828A1 (en) | 2006-03-16 |
WO2006029275A3 (en) | 2006-07-27 |
JP2008512479A (ja) | 2008-04-24 |
IL181315A0 (en) | 2007-07-04 |
CN101048428A (zh) | 2007-10-03 |
NZ553171A (en) | 2010-03-26 |
US20070231324A1 (en) | 2007-10-04 |
KR20070050951A (ko) | 2007-05-16 |
BRPI0515604A (pt) | 2008-07-29 |
EP1802660A2 (en) | 2007-07-04 |
NO20071789L (no) | 2007-06-05 |
RU2007112952A (ru) | 2008-10-20 |
WO2006029275A2 (en) | 2006-03-16 |
US20090175854A1 (en) | 2009-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20080044421A1 (en) | Methods of using death receptor ligands and CD20 antibodies | |
US20070231324A1 (en) | Methods of using death receptor ligands and CD20 antibodies | |
MX2007002856A (es) | Metodos para el uso de ligandos receptores de muerte y anticuerpos c20. | |
WO2009140469A2 (en) | Methods of using apo2l/trail to treat cancer | |
AU2002250352C1 (en) | Combination therapy | |
EP1192185B1 (en) | Apo-2L RECEPTOR AGONIST AND CPT-11 SYNERGISM | |
US20060188498A1 (en) | Methods of using death receptor agonists and EGFR inhibitors | |
JP2008500969A (ja) | Dr5抗体とその使用法 | |
JP2008529499A (ja) | 抗体変異体とその使用 | |
CA2532556A1 (en) | Assay for human anti cd20 antibodies and uses therefor | |
US20120189573A1 (en) | Methods of using death receptor agonists and EGFR inhibitors | |
JP2004509078A (ja) | Apo−2LレセプターアゴニストとCPT−11の相乗作用 | |
ZA200701723B (en) | Methods of using death receptor ligands and CD20 antibodies | |
AU2012201321A1 (en) | Methods of using death receptor agonists and EGFR inhibitors | |
EP1658859A1 (en) | APO-2L receptor agonist and CPT-11 synergism | |
MX2007009991A (en) | Methods of using death receptor agonists and egfr inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |